|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, CSE1L expression was correlated with depth of CRC.
|
30144787 |
2018 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
The upregulation of karyopherin α 2 (KPNA2) and chromosome segregation 1‑like (CSE1L) in colorectal carcinoma, in addition to downregulation of chloride channel accessory 1 (CLCA1), fatty acid binding protein 1 (FABP1), sodium channel, voltage gated, type VII α subunit (SCN7A) and solute carrier family 26 (anion exchanger), member 3 (SLC26A3) was confirmed.
|
27121919 |
2016 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
CSE1L was significantly increased during the transition from AD to CRC when compared with NR in a CRC tissue microarray (P = 0.01 and P < 0.001).
|
27521996 |
2016 |
|
Colorectal Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
CSE1L (chromosome segregation 1-like) gene maps to 20q13, a chromosomal region that correlates with colorectal cancer development.
|
23806821 |
2013 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
CSE1L, DIDO1 and RBM39 are located on the 20q amplicon and affect processes such as cell viability and anchorage-independent growth in colorectal cancer.
|
22711543 |
2012 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry of a colorectal cancer tissue microarray showed that CSE1L had a significantly increased level in colorectal cancer compared to normal colorectal epithelium (p < 0.001).
|
22450763 |
2012 |
|
Colorectal Carcinoma
|
0.360 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence.
|
29326435 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.
|
31299468 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of CSE1L was detected by immunohistochemistry in seminoma tissues and non-tumour normal testis tissues from patients.
|
30485574 |
2019 |
|
body fat percentage (physical finding)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
|
30593698 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence.
|
28530673 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of CTNB1, XPO2, and CAPG achieved 95% sensitivity and 96% specificity for the discrimination of these subtypes.<b>Conclusions:</b> We developed two uterine aspirate-based signatures to diagnose EC and classify tumors in the most prevalent histologic subtypes.
|
28790116 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, depletion of CAS by RNAi in the BRAF(V600E)-positive PTC cell line B-CPAP led to reduced tumor cell growth measured by crystal violet assays.
|
26892809 |
2016 |
|
Unipolar Depression
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Mood Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Major Depressive Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
|
27622933 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CAS/imp-α1 transport cycle is linked to XIAP and is required to maintain tumor cell survival in HCC.
|
24799195 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Colorectal tumors with K-Ras mutation or high cytoplasmic CSE1L expression were correlated with T status (depth of tumor penetration; P = .004), stage (P = .004), and lymph node metastasis (P = .019).
|
23806821 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry revealed that CSE1L is upregulated in oligodendroglial tumors.
|
23252729 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There were significant decreases in both nuclear (p = 0.006) and cytoplasmic (p = 0.003) staining of CSE1L in tumours with lymph node metastasis (stage 3 tumours) compared with lymph node-negative tumours (stage 1 and 2 tumours).
|
22450763 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which currently is in a phase II-clinical trial in patients against metastatic prostate cancer, exhibits anti-tumor activity via inhibition of tumor angiogenesis in human and rodent tumors.
|
20470445 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Significant reciprocal correlation was observed between high levels of CAS and histologic type, FIGO (International Federation of Obstetrics and Gynecology) stage III and grade 3, residual tumor (>2 cm), 20q13.2 (ZNF217 gene) amplification (>4 copies in >20% cells), and high expression of cyclin D1 (all P < .05).
|
12472286 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In neoplastic tissue, CAS was present in 93% of the tumors, Bax in 88%, caspase-3 in 77%, and Bcl-2 in 51%.
|
11603220 |
2001 |